ATOWW (Atossa Therapeutics) Ending Cash Position : $71.19 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Atossa Therapeutics Ending Cash Position?

Atossa Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 was $71.19 Mil.

Atossa Therapeutics's quarterly Ending Cash Position declined from Jun. 2024 ($79.64 Mil) to Sep. 2024 ($74.88 Mil) and declined from Sep. 2024 ($74.88 Mil) to Dec. 2024 ($71.19 Mil).

Atossa Therapeutics's annual Ending Cash Position declined from Dec. 2022 ($111.00 Mil) to Dec. 2023 ($88.57 Mil) and declined from Dec. 2023 ($88.57 Mil) to Dec. 2024 ($71.19 Mil).

Atossa Therapeutics Ending Cash Position Historical Data

The historical data trend for Atossa Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Ending Cash Position Chart

Atossa Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

39.66

136.49

111.00

88.57

71.19

Atossa Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															88.57	84.07	79.64	74.88	71.19

Atossa Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Atossa Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	88.57	+	-17.376
	=	71.19

Atossa Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	74.876	+	-3.682
	=	71.19

Atossa Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (OTCPK:ATOWW) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ATOS:USA ATOS:Mexico YAG2:Germany

Address

10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.